Your browser is no longer supported. Please, upgrade your browser.
Settings
EPZM Epizyme, Inc. daily Stock Chart
EPZM [NASD]
Epizyme, Inc.
Index- P/E- EPS (ttm)-2.06 Insider Own0.10% Shs Outstand74.78M Perf Week-1.45%
Market Cap1.27B Forward P/E- EPS next Y-2.44 Insider Trans163.76% Shs Float50.26M Perf Month7.62%
Income-119.90M PEG- EPS next Q-0.65 Inst Own84.60% Short Float13.22% Perf Quarter15.31%
Sales17.10M P/S74.12 EPS this Y41.90% Inst Trans2.33% Short Ratio11.47 Perf Half Y-1.17%
Book/sh2.57 P/B6.60 EPS next Y-3.40% ROA-49.90% Target Price23.78 Perf Year74.02%
Cash/sh2.58 P/C6.57 EPS next 5Y- ROE-63.10% 52W Range8.38 - 20.00 Perf YTD40.08%
Dividend- P/FCF- EPS past 5Y33.30% ROI-55.30% 52W High-15.25% Beta2.21
Dividend %- Quick Ratio7.70 Sales past 5Y2.90% Gross Margin- 52W Low102.39% ATR1.16
Employees112 Current Ratio7.70 Sales Q/Q2014.20% Oper. Margin- RSI (14)51.76 Volatility8.14% 6.83%
OptionableYes Debt/Eq0.00 EPS Q/Q1.60% Profit Margin- Rel Volume1.76 Prev Close18.70
ShortableYes LT Debt/Eq0.00 EarningsNov 03 BMO Payout- Avg Volume579.22K Price16.95
Recom1.50 SMA20-2.85% SMA5012.65% SMA20019.26% Volume1,018,987 Change-9.36%
Sep-20-17Initiated Jefferies Buy $23
May-10-17Resumed RBC Capital Mkts Outperform $19 → $20
Apr-13-17Initiated Oppenheimer Outperform
May-10-16Reiterated Mizuho Buy $20 → $18
Apr-05-16Initiated Citigroup Buy $17
Mar-14-16Upgrade H.C. Wainwright Neutral → Buy $25
Mar-10-16Reiterated Wedbush Outperform $33 → $22
Mar-10-16Reiterated Mizuho Buy $26 → $20
Mar-09-16Reiterated RBC Capital Mkts Outperform $39 → $26
Aug-06-15Reiterated Mizuho Buy $29 → $26
Jul-20-15Downgrade H.C. Wainwright Buy → Neutral $45 → $22
Jul-06-15Initiated RBC Capital Mkts Outperform $40
Mar-13-15Reiterated Mizuho Buy $35 → $29
Sep-12-14Initiated Mizuho Buy $35
Aug-13-14Reiterated H.C. Wainwright Buy $40 → $45
Jul-15-14Initiated H.C. Wainwright Buy $40
Jun-25-13Initiated Cowen Outperform
Sep-20-17 08:31AM  Epizyme (EPZM) Looks Good: Stock Adds 7.8% in Session Zacks
Sep-19-17 06:30AM  Epizyme Announces Closing of Public Offering of Common Stock GlobeNewswire +7.84%
Sep-15-17 04:30PM  Why Blue Apron Holdings, Tailored Brands, and Epizyme Jumped Today Motley Fool +7.50%
Sep-14-17 10:19AM  Is It Too Late To Buy Epizyme Inc (EPZM)? Simply Wall St.
06:30AM  Epizyme Announces Pricing of Public Offering of Common Stock GlobeNewswire
Sep-13-17 04:01PM  Epizyme Announces Proposed Public Offering of Common Stock GlobeNewswire -6.73%
Aug-30-17 06:30AM  Epizyme to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-15-17 06:30AM  Epizyme Announces Leadership Transition for Finance Organization GlobeNewswire
Aug-11-17 07:11PM  Edited Transcript of EPZM earnings conference call or presentation 4-Aug-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-07-17 04:09PM  Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2 Zacks
08:34AM  Epizyme, Inc. breached its 50 day moving average in a Bullish Manner : EPZM-US : August 7, 2017 Capital Cube
Aug-04-17 09:38PM  Epizyme reports 2Q loss Associated Press +13.65%
10:43AM  Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring TheStreet.com
08:23AM  Epizyme (EPZM) Reports Narrower-than-Expected Q2 Loss Zacks
06:30AM  Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress GlobeNewswire
06:00AM  Investor Network: Epizyme, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 07:40AM  Featured Company News - US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations ACCESSWIRE
Aug-01-17 06:29PM  What to Expect from Epizyme (EPZM) This Earnings Season? Zacks +5.26%
06:30AM  US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations GlobeNewswire
Jul-31-17 06:30AM  Epizyme Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference GlobeNewswire -6.17%
Jul-24-17 04:05PM  Epizyme Announces Tazemetostat to be Evaluated in NCIs Recently Initiated NCI-COG Pediatric MATCH Trial GlobeNewswire
Jul-18-17 09:33AM  Epizyme, Inc. breached its 50 day moving average in a Bearish Manner : EPZM-US : July 18, 2017 Capital Cube
Jun-30-17 03:49PM  Epizyme, Inc. Value Analysis (NASDAQ:EPZM) : June 30, 2017 Capital Cube
Jun-29-17 08:53AM  Epizyme, Inc. breached its 50 day moving average in a Bullish Manner : EPZM-US : June 29, 2017 Capital Cube
Jun-26-17 08:25AM  Epizyme Progressing Well on Two Lead Pipeline Candidates Zacks
06:30AM  Epizyme Expands Clinical Collaboration to Study Tazemetostat and TECENTRIQ® Combination in NSCLC GlobeNewswire
Jun-21-17 09:36AM  Biotech Movers: Sangamo, Epizyme, Revance TheStreet.com +5.45%
Jun-20-17 09:33AM  Biotech Movers: AveXis, Clovis, Epizyme TheStreet.com
Jun-16-17 01:06PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily -5.86%
08:35AM  Epizyme (EPZM) Jumps: Stock Rises 17.4% Zacks
Jun-15-17 08:33PM  Why Epizyme Inc.'s Shares Are Skyrocketing Today Motley Fool +17.41%
04:28PM  Why Epizyme, Tribune Media, and Revlon Jumped Today Motley Fool
04:10PM  Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J TheStreet.com
03:20PM  Could This Small Biotech Pique Interest Of Gilead And Others? Investor's Business Daily
09:00AM  Epizyme Provides Positive Interim Data on EZH2 Inhibitor Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Epizyme and Alexion Pharmaceuticals Accesswire
Jun-14-17 04:44PM  Epizyme Inc (EPZM) Ends Positive After a Rollercoaster Ride; Oppenheimer Weighs in SmarterAnalyst +10.76%
04:32PM  Why SeaWorld Entertainment, Brookdale Senior Living, and Epizyme Jumped Today Motley Fool
12:22PM  Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data TheStreet.com
08:30AM  Epizyme Reports Positive Interim Data from Phase 2 Trial for Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL Patients GlobeNewswire
Jun-13-17 03:41AM  Epizyme (EPZM) Down 19.2% Since Earnings Report: Can It Rebound? Zacks
Jun-05-17 01:48PM  Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data Benzinga -6.55%
Jun-01-17 07:20AM  A New Era of Cancer Research as ASCO Kicks Off 24/7 Wall St.
May-26-17 09:49AM  3 Stocks With iRobot-Like Return Potential Motley Fool
08:28AM  Epizyme, Inc. breached its 50 day moving average in a Bearish Manner : EPZM-US : May 26, 2017 Capital Cube
May-18-17 08:43AM  Implied Volatility Surging for Epizyme (EPZM) Stock Options Zacks
06:00AM  Epizyme Announces Path Toward Tazemetostat Registration in Epithelioid Sarcoma and Reports New Clinical Data to be Presented at ASCO GlobeNewswire
May-17-17 10:07AM  Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth Zacks
May-10-17 08:00AM  Today's Research Reports on Stocks to Watch: Insys Therapeutics and Epizyme Accesswire
May-09-17 09:50AM  Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1 Zacks
08:55AM  Epizyme, Inc. breached its 50 day moving average in a Bearish Manner : EPZM-US : May 9, 2017 Capital Cube
May-08-17 07:58AM  Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss Zacks -6.75%
07:04AM  Epizyme reports 1Q loss Associated Press
07:00AM  Epizyme Reports First Quarter 2017 Results and Provides Corporate Update GlobeNewswire
May-05-17 08:22AM  3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month Motley Fool
May-04-17 06:30AM  Epizyme Earns $10 Million Milestone Payment from GlaxoSmithKline for Initiation of GLP Toxicology Studies with Novel Methyltransferase Inhibitor GlobeNewswire
May-03-17 04:36PM  What to Expect from Epizyme (EPZM) This Earnings Season? Zacks
Apr-27-17 04:48PM  Epizyme, Inc. Value Analysis (NASDAQ:EPZM) : April 27, 2017 Capital Cube
Apr-26-17 08:38AM  Epizyme, Inc. breached its 50 day moving average in a Bullish Manner : EPZM-US : April 26, 2017 Capital Cube
Apr-25-17 02:01PM  Why Epizyme Inc. Shares Are Soaring Today Motley Fool +17.11%
06:30AM  Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML GlobeNewswire
Apr-20-17 10:05AM  Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO GlobeNewswire
Apr-14-17 08:05AM  Epizyme, Inc. breached its 50 day moving average in a Bullish Manner : EPZM-US : April 14, 2017 Capital Cube
Apr-10-17 07:25AM  Why Is Epizyme (EPZM) Down 3.6% Since the Last Earnings Report? Zacks
Apr-07-17 04:26PM  ETFs with exposure to Epizyme, Inc. : April 7, 2017 Capital Cube
Mar-29-17 06:30AM  Epizyme to Present New Preclinical Data on Tazemetostat and Epigenetic Target Identification Efforts at AACR Annual Meeting GlobeNewswire
Mar-20-17 09:19AM  Epizyme, Inc. :EPZM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
09:19AM  Epizyme, Inc. :EPZM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-16-17 01:04PM  EPIZYME, INC. Financials
Mar-15-17 02:02PM  Epizyme, Inc. :EPZM-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Capital Cube
02:02PM  Epizyme, Inc. :EPZM-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
Mar-13-17 07:04AM  EPIZYME, INC. Files SEC form 10-K, Annual Report
Mar-10-17 10:30AM  Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus Zacks +9.87%
Mar-09-17 11:21PM  Edited Transcript of EPZM earnings conference call or presentation 9-Mar-17 1:30pm GMT Thomson Reuters StreetEvents
08:57AM  Epizyme (EPZM) Reports A Narrower Q4 Loss Zacks
08:30AM  Epizyme Inc Earnings Call scheduled for 8:30 am ET today
07:07AM  Q4 2016 Epizyme Inc Earnings Release - Before Market Open
06:40AM  Epizyme reports 4Q loss Associated Press
06:37AM  EPIZYME, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
06:32AM  Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals GlobeNewswire
06:30AM  Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company GlobeNewswire
Mar-06-17 06:34PM  Can Epizyme (EPZM) Spring a Surprise This Earnings Season?
Feb-27-17 09:06AM  Epizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call Date and March Investor Conferences GlobeNewswire +12.35%
Feb-07-17 04:34PM  EPIZYME, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
06:30AM  Epizyme Elects Kevin Conroy to its Board of Directors GlobeNewswire
Feb-02-17 06:30AM  Epizyme to Present at Upcoming Investor Conferences GlobeNewswire +9.22%
Jan-19-17 08:50AM  EPIZYME, INC. Files SEC form 8-K, Other Events
Jan-13-17 07:09AM  Pluristem (PSTI) Intermittent Claudication Study Enrolled
Jan-12-17 04:19PM  TherapeuticsMD's Rejoice Study Data Published in Journal
07:47AM  Gilead (GILD) HBV Drug Vemlidy Receives European Approval
Jan-11-17 08:47AM  Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU
Jan-10-17 05:55PM  New England Venture Capital Association adds new board members at bizjournals.com
08:50AM  AbbVie's HCV Combo Favorable in Japanese Phase III Study
Jan-09-17 06:07PM  Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
08:10AM  Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
08:02AM  EPIZYME, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-03-17 06:30AM  Epizyme Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference GlobeNewswire
Dec-19-16 12:15PM  Moving Average Crossover Alert: Epizyme (EPZM)
Dec-08-16 12:25PM  Should You Add Epizyme Inc (EPZM) to Your Portfolio? at Insider Monkey
Nov-29-16 08:56AM  Epizyme Tazemetostat Gets Fast Track Designation in U.S.
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Celgene RIVOT Ltd., Genentech Inc., Glaxo Group Limited, and US Oncology Research, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOTT DAVID MDirectorSep 18Buy15.25200,0003,050,0006,054,351Sep 18 04:27 PM
Ho Peter Tai-ChingChief Development OfficerAug 24Option Exercise8.9815,000134,70022,228Aug 28 01:39 PM
Ho Peter Tai-ChingChief Development OfficerAug 24Sale15.6815,000235,2667,228Aug 28 01:39 PM
Ho Peter Tai-ChingChief Development OfficerJul 24Option Exercise8.9815,000134,70022,228Jul 26 05:19 PM
Ho Peter Tai-ChingChief Development OfficerJul 24Sale13.4415,000201,5727,228Jul 26 05:19 PM
Singer Andrew E.EVP & CFOJun 30Sale15.503,02446,87240,529Jul 05 03:47 PM
Ho Peter Tai-ChingChief Development OfficerJun 26Option Exercise8.9815,000134,70022,228Jun 27 03:13 PM
Ho Peter Tai-ChingChief Development OfficerJun 26Sale14.8715,000223,1157,228Jun 27 03:13 PM
Copeland Robert APresident of Research and CSOJun 06Option Exercise3.542,5008,85034,038Jun 07 01:48 PM
Copeland Robert APresident of Research and CSOJun 06Sale13.452,50033,62531,538Jun 07 01:48 PM
Ho Peter Tai-ChingChief Development OfficerMay 25Option Exercise8.9815,000134,70022,228May 26 11:20 AM
Ho Peter Tai-ChingChief Development OfficerMay 25Sale16.1115,000241,6647,228May 26 11:20 AM
Copeland Robert APresident of Research and CSOMay 02Option Exercise3.545,00017,70036,538May 03 01:08 PM
Copeland Robert APresident of Research and CSOMay 02Sale17.445,00087,21331,538May 03 01:08 PM
Copeland Robert APresident of Research and CSOApr 04Option Exercise3.005,00015,00036,538Apr 05 05:44 PM
Copeland Robert APresident of Research and CSOApr 04Sale16.365,00081,80531,538Apr 05 05:44 PM
Singer Andrew E.EVP & CFOMar 31Sale17.092,01334,39436,175Apr 03 01:55 PM
Singer Andrew E.EVP & CFOJan 09Sale12.041,01312,19433,270Jan 10 02:01 PM
Singer Andrew E.EVP & CFODec 09Sale11.031,01311,17231,824Dec 12 02:46 PM
Ho Peter Tai-ChingChief Development OfficerDec 08Sale10.892002,1795,520Dec 12 02:48 PM
Singer Andrew E.EVP & CFONov 09Sale10.401,01310,53530,378Nov 10 09:28 PM
Singer Andrew E.EVP & CFOOct 10Sale9.721,0139,84828,931Oct 12 01:42 PM